Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Metformin in Resectable Pancreatic Ductal Adenocarcinoma
NCT02978547Phase 2Unknown
- Sponsor
- BC Cancer
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in pancreatic ductal adenocarcinoma (PDAC), sponsored by BC Cancer. Primary endpoint: The effect of neoadjuvant metformin treatment on tumour cell proliferation in PDAC tumours at 6 months. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02978547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978547.